Background {#s1}
==========

Nilotinib is a BCR-ABL tyrosine kinase inhibitor with superior potency to imatinib. Elevations in serum aminotransferases may occur during nilotinib therapy, but elevations greater than 5 times the upper limit of normal is a rare event. Until now, the precise mechanism of the liver injury by nilotinib is largely unknown. Here, we report a patient who developed severe immune-mediated liver injury by nilotinib treatment. Written informed consent was obtained from the patient described in this case report.

Case Summary {#s2}
============

A 59-year-old woman was referred to the liver clinic because of elevated liver enzyme levels.

One year prior, she was diagnosed as having chronic myeloid leukemia. The patient was carrying the e14a2 (b3a2) BCR-ABL1 transcript. Initially, dasatinib treatment was started, but the drug caused intractable pleural effusion. Dasatinib was changed to nilotinib (300 mg, twice a day). Four months of nilotinib treatment resulted in the complete hematologic response in bone marrow examination, although it caused elevation of serum aminotransferase levels. Nilotinib was temporarily stopped, and liver enzymes became normalized. However, retrial of nilotinib after one month of drug holiday caused liver enzymes to rise more rapidly ([Figure 1](#F1){ref-type="fig"}). She did not drink alcohol and denied taking any medications except for nilotinib.

![Summary of the patient progress after the diagnosis with chronic myeloid leukemia.](fonc-10-01160-g0001){#F1}

The hemoglobin level was 13.8 g/dL; leukocyte count, 4,320/μL; and platelet count, 123,000/μL. There was no eosinophilia. Her aspartate aminotransferase level was 578 IU/L; alanine aminotransferase level, 499 IU/L; alkaline phosphatase level, 110 IU/L; gamma-glutamyl transferase level, 180 U/L; and total bilirubin level, 1.51 mg/dL. The prothrombin time was not prolonged. Test results for HBsAg, anti-HAV IgM antibody, anti-HCV antibody, and anti-HEV IgM antibody were negative. Serological results for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus were all negative. The serum immunoglobulin G level was 1,383 mg/dL. The antinuclear antibody titer was 1:320. Results for anti-liver/kidney microsomal, anti-mitochondrial, anti-smooth muscle, and anti-neutrophil cytoplasmic antibodies were negative. Ultrasonography revealed a mildly increased peripheral echogenicity, without evidence of chronic liver disease or biliary obstruction.

Percutaneous needle liver biopsy on the second day showed extensive centrilobular infiltration of immune cells and destruction of the lobular architecture (solid-lined square) with minimal inflammation in the portal triad (dot-lined square; [Figure 2A](#F2){ref-type="fig"}). Portal or perisinusoidal fibrosis was not detected. Immunohistochemical staining for CD8 showed that numerous CD8^+^ T cells were in contact with dying hepatocytes ([Figure 2B](#F2){ref-type="fig"}). CD56 staining demonstrated that many CD56^+^ cells, including natural killer (NK) cells, also infiltrated the site of inflammation (arrowheads; [Figure 2C](#F2){ref-type="fig"}). Multicolor fluorescence-activated cell-sorting analysis using liver biopsy specimens revealed that a considerable number of intrahepatic CD8^+^ T cells in the patient (42.4%) showed an activated phenotype (CD38^+^ HLA-DR^+^) compared with those in the healthy liver (8.9%; [Figure 2D](#F2){ref-type="fig"}).

![**(A)** Hematoxylin and eosin-stained section (Original magnification X100). Solid-lined square focuses on the centrilobular architecture and dot-lined square depicts the portal triad. **(B)** CD8 stain (Original magnification X200). **(C)** CD56 stain (Original magnification X200). **(D)** CD38 and HLA-DR staining results of intrahepatic CD8^+^ T cells.](fonc-10-01160-g0002){#F2}

She was diagnosed with nilotinib-induced, immune-mediated liver injury. Prednisolone treatment (30 mg daily) was started and caused rapid normalization of liver enzyme levels ([Figure 1](#F1){ref-type="fig"}). Prednisolone was gradually tapered and stopped after 14 days of use. After cessation of the corticosteroid therapy, the liver enzyme level remained normalized.

Discussion {#s3}
==========

Nilotinib is a drug approved for the treatment of chronic myeloid leukemia by the Food and Drug Administration in 2007. The phase 3 randomized trial showed that nilotinib was superior to imatinib in major molecular and cytogenetic response ([@B1]). The incidence of grade 3 or 4 elevation of liver enzymes caused by nilotinib was reported 1 to 4% ([@B2]). Belopolsky et al. reported a case of the patient with nilotinib-induced grade 4 hepatotoxicity, which was normalized after the cessation of nilotinib ([@B3]). In that report, the liver biopsy showed acute hepatitis with severe portal and lobular inflammation, although the exact types of infiltrating immune cells or their activation status were not studied ([@B3]). There have also been several case reports of imatinib-induced liver injury, which did not identify the actual "killer cells" in the liver.

The mechanism of drug-induced liver injury (DILI) is heterogeneous and includes direct hepatotoxicity, immune-mediated liver injury, and mitochondria-selective toxicity ([@B4]). Several drugs have been reported to cause "immune-mediated DILI." Sometimes, these patients may be indistinguishable from those with autoimmune hepatitis on the basis of their histological and clinical presentations ([@B5], [@B6]). The latency period between drug exposure and the onset of the disease can vary from 1 week to more than 3 months in the cases of immune-mediated DILI ([@B5], [@B6]). The absence of advanced fibrosis or cirrhosis, together with the features of hypersensitivity, a latency period to liver injury from drug exposures, and published reports on the suspected drug may support the diagnosis of immune-mediated DILI ([@B7]). Neoantigens are formed during the metabolism of the causative agent, and presented by antigen-presenting cells and hepatocytes. After priming, neoantigen-specific cytotoxic CD8^+^ cells may be expanded in the liver or migrate from circulation ([@B7]). Analysis of liver-infiltrating lymphocytes from the patients with immune-mediated DILI demonstrated that the number of activated CD8^+^ T-cells correlates with the degree of liver injury ([@B7], [@B8]). Serum aminotransferase levels \> 3-fold upper normal limit (UNL) and total serum bilirubin level \> 2-fold UNL may require corticosteroid therapy ([@B5]). Sustained biochemical resolution following the withdrawal of corticosteroid confirms the diagnosis of immune-mediated DILI rather than autoimmune hepatitis.

In our patient, liver biopsy showed extensive centrilobular infiltration of CD8^+^ T cells and NK cells, so-called "killer" cells, which suggests immune-mediated liver injury. The findings that most of the intrahepatic CD8^+^ T cells showed an activated phenotype (CD38^+^ HLA-DR^+^) are consistent with those of a recent study that demonstrated that activated CD8^+^ T cells of acute hepatitis A patients exert innate-like cytotoxicity, which is associated with liver injury ([@B9]). During acute hepatitis A, a considerable number of CD8^+^ T cells are activated in a T cell receptor-independent manner, and this phenomenon may also occur in the inflamed liver with activated killer cells triggered by certain drugs ([@B10]). The limitations of this report are as follows: First, there was the possibility of other causes of liver injury in our patient. Second, we are reporting only one case. Future studies with more cases are needed to validate of this report. In summary, our case shows immune-mediated liver injury by nilotinib and the possibility of therapeutic use of corticosteroids in immune-mediated liver injury.
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